BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 1974826)

  • 1. Immunosuppression in murine renal cell carcinoma. II. Identification of responsible lymphoid cell phenotypes and examination of elimination of suppression.
    Gregorian SK; Battisto JR
    Cancer Immunol Immunother; 1990; 31(6):335-41. PubMed ID: 1974826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppression in murine renal cell carcinoma. I. Characterization of extent, severity and sources.
    Gregorian SK; Battisto JR
    Cancer Immunol Immunother; 1990; 31(6):325-34. PubMed ID: 2386978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved lymphocyte cytotoxicity against murine renal cell carcinoma.
    Salup RR; Sicker DC; Ballou BT; Flack CE; Wolmark N; Hakala TR
    J Urol; 1992 Feb; 147(2):491-5. PubMed ID: 1732630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostaglandin-mediated inactivation of natural killer cells in the murine decidua.
    Scodras JM; Parhar RS; Kennedy TG; Lala PK
    Cell Immunol; 1990 May; 127(2):352-67. PubMed ID: 2139365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
    Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
    BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the host natural killer cell population in mice during tumor development. 2. The mechanism of suppression of NK activity.
    Parhar RS; Lala PK
    Cell Immunol; 1985 Jul; 93(2):265-79. PubMed ID: 3159480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines.
    Suchorska WM; Dams-Kozlowska H; Kazimierczak U; Wysocki PJ; Mackiewicz A
    Expert Opin Biol Ther; 2011 Dec; 11(12):1555-67. PubMed ID: 21995459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin E2-mediated inactivation of various killer lineage cells by tumor-bearing host macrophages.
    Parhar RS; Lala PK
    J Leukoc Biol; 1988 Dec; 44(6):474-84. PubMed ID: 2973508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumor-bearing mice and prevents tumor metastasis.
    Lala PK; Parhar RS; Singh P
    Cell Immunol; 1986 Apr; 99(1):108-18. PubMed ID: 2944621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chinese medicinal herbs inhibit growth of murine renal cell carcinoma.
    Lau BH; Ruckle HC; Botolazzo T; Lui PD
    Cancer Biother; 1994; 9(2):153-61. PubMed ID: 7812364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
    J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor site-dependent differential modulation of systemic immunity in RENCA bearing mice.
    Yoon HL; Choi KM; Jung YS; Park CH; Yoon SS
    In Vivo; 1999; 13(5):407-13. PubMed ID: 10654194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour-induced suppression of immune response and its correction.
    Banat GA; Christ O; Cochlovius B; Pralle HB; Zöller M
    Cancer Immunol Immunother; 2001 Jan; 49(11):573-86. PubMed ID: 11225988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential induction of suppressor macrophages by cloned Lewis lung carcinoma variants in mice.
    Young MR; Newby M
    J Natl Cancer Inst; 1986 Dec; 77(6):1255-60. PubMed ID: 3491925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional and phenotypic characteristics of recombinant interleukin-2 or T-cell growth factor-activated splenic lymphoid cells from patients with gastric or hepatocellular carcinoma.
    Ebihara T; Fukao K; Koyama S
    Cancer; 1990 Sep; 66(5):923-9. PubMed ID: 2167147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
    Doehn C; Esser N; Pauels HG; Kiessig ST; Stelljes M; Grossmann A; Jocham D; Drevs J
    Eur Urol; 2009 Jul; 56(1):123-31. PubMed ID: 18550267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine-activated killer cells.
    Sedlmayr P; Rabinowich H; Elder EM; Ernstoff MS; Kirkwood JM; Herberman RB; Whiteside TL
    J Immunother (1991); 1991 Oct; 10(5):336-46. PubMed ID: 1790141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostaglandin E2-mediated suppression of murine lymphokine-activated killer cell activity generated from tumor-bearing hosts by interferon-gamma.
    Nakajima I; Chu TM
    Mol Biother; 1990 Dec; 2(4):228-32. PubMed ID: 2126942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal cell carcinoma and natural killer cells: studies in a novel rat model in vitro and in vivo.
    Winter BK; Wu S; Nelson AC; Pollack SB
    Cancer Res; 1992 Nov; 52(22):6279-86. PubMed ID: 1423274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophage-mediated suppression of natural killer cell activity in mice bearing Lewis lung carcinoma.
    Young MR; Wheeler E; Newby M
    J Natl Cancer Inst; 1986 Apr; 76(4):745-50. PubMed ID: 3457207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.